Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium

Publication Name: Press Release

Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating  the SymphonyTM suite of genomic tests (MammaPrint®, BluePrint® … Continued

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer

Publication Name: Cancer Research

Author(s): C.A. Drukker, M.V. Nijenhuis, S.G.Elias, J. Wesseling, N.S. Russell, P. Whitworth, R. Patel, F. de Snoo, L.J. van’t Veer, P.D. Beitsch, E.J.Th. Rutgers

The 70-­‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-­‐gene signature result compared to those with high risk 70-­‐gene signature result, independent … Continued

Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments

Publication Name: Poster, SABCS 2008

Author(s): Paul Roepman, Hugo Horlings, Oscar Krijgsman, Jolien Bueno-de-Mesquita, Richard Bender, Sabine Linn, Annuska Glas and Marc van de Vijver

In breast cancer patients the level of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 is predictive for prognosis and/or treatment response. However, differences in assessment methods and interpretation can substantially affect the accuracy and reproducibility of the … Continued